Mitsubishi UFJ Asset Management’s Apogee Therapeutics APGE Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$597K	Buy	+4,500	New	+$405K	﹤0.01%	896

Other funds holding APGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

AIMCA

Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $17.9B AUM 27.57% 1-Year Est. Return

Mitsubishi UFJ Asset Management's APGE Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 4,500 shares worth $597K. The stake represents ﹤0.01% of the portfolio and ranks #896 among its holdings.

77 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Mitsubishi UFJ Asset Management held 4,500 shares of Apogee Therapeutics worth $597K as of Q2 2026.
Apogee Therapeutics was a new Mitsubishi UFJ Asset Management position in Q2 2026.
Apogee Therapeutics made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #896 holding.
77 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.